Key result
Early vascular aging shares bidirectional links with hypertension, driven by hemodynamic and metabolic factors.
Why the study?
The aging process takes a more rapid course in some individuals, reflected in the Early Vascular Aging (EVA) syndrome linked to hypertension and non-hemodynamic factors, while mapping protective mechanisms in Healthy or Super Normal Vascular Aging could identify new preventive drug targets.
Early Vascular Aging (EVA), defined by increased arterial stiffness and pulse wave velocity, interacts bidirectionally with hypertension and metabolic factors, offering novel targets for cardiovascular risk stratification and preventive therapy.
Answers are grounded in this paper and cite their sources.
May inform hypertension risk stratification via PWV; leaves open need for trials targeting metabolic drivers of early vascular aging.
With increasing age, the cardiovascular risk increases, as does frailty, with negative health consequences such as coronary disease, stroke, and vascular dementia. However, this aging process seems to take a more rapid course in some individuals, as reflected in the Early Vascular Aging (EVA) syndrome that over the recent 10 years has attracted increased attention. The core of the EVA syndrome is arterial stiffness in the media layer of large elastic arteries, a process that can be measured by pulse wave velocity, for example, along the aorta. Hypertension is a well-known cardiovascular risk factor in its own right, but also linked to the EVA process. However, several studies have shown that non-hemodynamic factors also contribute to arterial stiffness and EVA, such as impaired glucose metabolism, chronic inflammation, and oxidative stress. New perspectives have been introduced for linking early life programming affecting new-born babies and birth weight, with a later risk of hypertension, arterial stiffness and EVA. New drugs are being developed to treat EVA when lifestyle intervention and conventional risk factor controlling drugs are not enough. Finally, the opposite phenotype of EVA is Healthy Vascular Aging (HVA) or even Super Normal Vascular Aging (SUPERNOVA). If protective mechanisms can be found and mapped in these fortunate subjects with a slower than expected aging process, there could exist a potential to find new drug targets for preventive therapy.
No takes yet. Share an insight, caveat, or question.
Peter M. Nilsson (2020) conducted a review in Hypertension and Early Vascular Aging (EVA). Antihypertensive and cardiometabolic therapies (e.g., RAS blockers, empagliflozin) was evaluated on Arterial stiffness measured by carotid-femoral pulse wave velocity (c-f PWV) and cardiovascular risk. Early Vascular Aging, characterized by elevated aortic pulse wave velocity, shares bidirectional links with hypertension and is driven by both hemodynamic and non-hemodynamic metabolic factors.
Synapse has enriched 10 related papers. Consider them for comparative context: